Loading clinical trials...

Use of Text Messaging Reminders to Increase FIT Completion Among Patients at the NYU FHCs | Clinical Trials | Clareo Health

COMPLETEDNA

Use of Text Messaging Reminders to Increase FIT Completion Among Patients at the NYU FHCs

Use of Text Messaging Reminders to Increase FIT Completion Among Patients at the New York University (NYU) Family Health Centers (FHCs)

NCT06632054•NYU Langone Health

View on ClinicalTrials.gov

Summary

The research team will compare the efficacy of targeted text message reminders against currently used phone call reminders at increasing patient completion of fecal immunochemical test (FIT) for colon cancer screening.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Adult patients eligible for FIT at a Family Health Center clinic (excluding Flatbush locations).

Locations (1)

NYU Langone Health

New York, New York, United States

Key Dates

Start Date

April 7, 2025

Primary Completion Date

June 24, 2025

Completion Date

July 15, 2025

Last Updated

December 19, 2025

Enrollment

1,283

ACTUAL participants

Conditions

Colon Cancer

Interventions

Text Message Reminders

BEHAVIORAL

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGNA

Resilience and Equity in Aging, Cancer, and Health (REACH)

NCT04674267

Gastric CancerColon Cancer+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Use of Text Messaging Reminders to Increase FIT Completion Among Patients at the NYU FHCs

Inclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Resilience and Equity in Aging, Cancer, and Health (REACH)

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Phase II Trial of Lung Chemoemobolization

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression